Back to School: How biopharma can reboot drug development. Access exclusive analysis here

IDM Pharma's mifamurtide not approvable

IDMI was off $0.38 (19%) to $1.64 on Monday after receiving a not approvable letter from FDA for an NDA

Read the full 206 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE